On November 4, 2026 Orca Bio, a commercial-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, reported that new clinical data will be presented in four poster sessions at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting from December 12-15 in New Orleans, LA, with one additional abstract accepted for online publication. The presentations will include two-year follow-up of TREGZI from the pivotal Phase 3 Precision-T trial, as well as data from ongoing studies evaluating Orca-T and the company’s next-generation candidate, Orca-Q.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Orca Bio is committed to advancing the science and body of evidence that support the value and potential of high-precision therapies in blood cancers," said J. Scott McClellan, MD, Ph.D., chief development officer of Orca Bio. "We look forward to sharing our data presentations at ASH (Free ASH Whitepaper), highlighting the results from the two-year follow up from the TREGZI pivotal trial, Precision-T, along with data exploring the benefit of Orca-T and Orca-Q across a range of transplant settings and patient types."
The ASH (Free ASH Whitepaper) abstracts are now available at www.hematology.org. Details of the Orca Bio poster presentations follow:
Poster Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I
Title: Trial in Progress: A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome (SERENE-T)
Publication Number: 2457
Date and Time: December 12, 2026 at 5:30 PM – 7:30 PM CST
Location: Ernest N. Morial Convention Center – Hall F
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I
Title: Clinical Overview of Acute GVHD Events with Orca-T Compares to Conventional Allograft with tac/MTX in Phase 3 Precision-T trial
Publication Number: 2485
Date and Time: December 12, 2026 at 5:30 PM – 7:30 PM CST
Location: Ernest N. Morial Convention Center – Hall F
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II
Title: Preliminary Outcomes of Reduced Intensity Conditioning or Nonmyeloablative Conditioning with Orca-Q in Matched Related and Matched Unrelated Donors
Publication Number: 4244
Date and Time: December 13, 2026 at 6:00 PM – 8:00 PM CST
Location: Ernest N. Morial Convention Center – Hall F
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II
Title: ACCESS-T: A Phase 1 Trial of Orca-T with Dual-Agent Tacrolimus/Ruxolitinib Prophylaxis for Myeloablative HLA-Mismatched Allogeneic HCT
Publication Number: 4227
Date and Time: December 13, 2026 at 6:00 PM – 8:00 PM CST
Location: Ernest N. Morial Convention Center – Hall F
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Title: Two-Year Follow-Up of Orca-T Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant Demonstrates Durable Survival Outcomes: Updated Results from the Precision-T Phase 3 Trial
Publication Number: 5992
Date and Time: December 14, 2026 at 6:00 PM – 8:00 PM CST
Location: Ernest N. Morial Convention Center – Hall F
Online Publication Only: Impact of Federal Eligibility Criteria for Donors on Post-Transplant Outcomes in the Orca-T Phase 3 Precision-T Trial
Publication Number: 8384
About TREGZI
TREGZI is the first-and-only FDA approved precision-cell therapy for allogeneic transplant in adults with hematologic malignancies to improve survival free of cGVHD. It is indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host-disease-free survival, in the treatment of adults with hematological malignancies.
TREGZI is a personalized treatment manufactured for each individual patient using living cells from a matched donor. TREGZI uses hematopoietic stem and progenitor cells (HSPCs) to reconstitute the immune system, highly purified regulatory T cells (Tregs) to suppress GVHD and conventional T cells (Tcons) to accelerate immune reconstitution and produce graft-versus-leukemia (GVL) activity.
The FDA approval of TREGZI was based on the results of Precision-T, a randomized, open-label, multi-center study that evaluated the safety, efficacy and tolerability of TREGZI compared with conventional allogeneic hematopoietic stem cell transplant (alloHSCT).
Click here for Important Safety Information.
About Orca-Q
Orca-Q is Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy under evaluation in clinical trials for the treatment of multiple hematologic malignancies, including in patients with haploidentical and mismatched donors. Orca-Q is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors and engineered by Orca Bio’s high-precision platform.
(Press release, Orca Bio, NOV 4, 2026, View Source [SID1234674235])